NDC 42385-929 – Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate

Efavirenz 400 mg/1; Lamivudine 300 mg/1; Tenofovir Disoproxil Fumarate 300 mg/1 · Tablet, Film Coated · Oral

Human Prescription Drug

Product NDC42385-929

Product details

Brand name
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Generic name
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Labeler
Laurus Labs Limited
Dosage form
Tablet, Film Coated
Route
Oral
Marketing category
ANDA · ANDA213038
Marketed since
May 14, 2020
Listing expires
December 31, 2026
Pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Active ingredients

Uses, dosage, side effects and warnings for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate →

Package NDC codes (6)

Package NDCDescriptionSince
42385-929-18180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)May 14, 2020
42385-929-3030 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)May 14, 2020
42385-929-3130 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)May 14, 2020
42385-929-82180 TABLET, FILM COATED in 1 BOTTLE (42385-929-82)May 14, 2020
42385-929-9090 TABLET, FILM COATED in 1 BOTTLE (42385-929-90)May 14, 2020
42385-929-9190 TABLET, FILM COATED in 1 BOTTLE (42385-929-91)May 14, 2020

Other Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate products